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The influence of polyvascular disease on the
obesity paradox in vascular surgery patients
Jan-Peter van Kuijk, MD,a Willem-Jan Flu, MD,a Wael Galal, MD,b Michel Chonchol, MD,c
Dustin Goei, MD,a Hence J. M. Verhagen, MD,a Jeroen J. Bax, MD,d and Don Poldermans, MD,a
Rotterdam and Leiden, The Netherlands; and Aurora, Colo
Background: Obesity is a risk factor for atherosclerosis, a polyvascular process associated with reduced survival. In
nonvascular surgery populations, a paradox between body mass index (BMI) and survival is described. This paradox
includes reduced survival in underweight patients, whereas overweight and obese patients have a survival benefit. No clear
explanation for this paradox has been given. Therefore, we evaluated the presence of the obesity paradox in vascular
surgery patients and the influence of polyvascular disease on the obesity paradox.
Methods: In this retrospective study, 2933 consecutive patients were classified according to their preoperative BMI
(kg/m2) and screened for polyvascular disease and cardiovascular risk factors before surgery. In addition, medication use
at the time of discharge was noted. Outcome was all-cause mortality during a median follow-up of 6.0 years (interquartile
range, 2-9 years).
Results: BMI (kg/m2) groups included 68 (2.3%) underweight (BMI <18.5), 1379 (47.0%) normal (BMI 18.5-24.9,
reference), 1175 (40.0%) overweight (BMI 25-29.9), and 311 (10.7%) obese (BMI >30) patients. No direct interaction
between BMI, polyvascular disease, and long-term outcome was observed. Underweight was an independent predictor of
mortality (hazard ratio, 1.65; 95% confidence interval, 1.22-2.22). In contrast, overweight protected for all-cause
mortality (hazard ratio, 0.79; 95% confidence interval, 0.700-0.89). Cardioprotective medication usage in underweight
patients was the lowest (P < .001), although treatment targets for risk factors were equally achieved within all treated
groups.
Conclusion:Overweight patients referred for vascular surgery were characterized by an increased incidence of polyvascular
disease and required more extensive medical treatment for cardiovascular risk factors at discharge. Long-term follow-up
showed a paradox of reduced mortality in overweight patients. ( J Vasc Surg 2011;53:399-406.)
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wThe prevalence of obesity among adults has been in-
creasing in epidemic proportions and has become a critical
problem in developed countries.1 The American Heart
Association and American College of Cardiology guide-
lines for secondary prevention in coronary artery disease
(CAD) have listed obesity as a major modifiable cardiovas-
cular risk factor.2 Obesity has an important role in the
atherosclerotic process because it promotes endothelial
dysfunction, systemic inflammation, and a prothrombotic
state.3 More important, the process of atherosclerosis is
often not limited to a single arterial location. The Reduc-
tion of Atherothrombosis for Continued Health registry
showed that one of six patients with peripheral arterial
disease (PAD), cerebrovascular disease, or CAD had in-
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doi:10.1016/j.jvs.2010.08.048olvement of one or two other arterial beds.4 Moreover,
he presence of polyvascular disease has been demonstrated
s an independent predictor of long-term cardiovascular
utcome in the general population.5-7
Although obesity is associated with an increased risk of
eveloping cardiovascular disease in the general popula-
ion, evidence from population-based studies with estab-
ished atherosclerotic disease has indicated an obesity par-
dox, whereby obesity appears to be protective against an
dverse prognosis.8-10 No clear explanation for this dis-
repancy in survival rates between increased body mass
ndex (BMI) and atherosclerotic disease has been found.
herefore, we performed the current study in a cohort of
ascular surgery patients to evaluate (1) the prevalence of
besity and the association on long-term survival and (2)
he association between polyvascular disease and medical
reatment at time of discharge with respect to obesity,
ardiovascular risk factor control, and long-term survival.
ETHODS
The study complies with the Declaration of Helsinki.
atient enrollment and approaching the municipal civil
egistries was performed after approval of the hospital’s
thics Committee.
Study design and population. This retrospective
ingle-center study comprised a source population of 3612
onsecutive major vascular operations, of which 254 (7%)
ere acute procedures and 3358 were elective (Fig 1). In
he 3358 elective operations, 2933 unique patients were
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February 2011400 van Kuijk et alidentified, and 425 repeated operations were performed in
311 (11%) of these 2933 patients. Patients who had more
than one operation were included only once, based on their
first surgical procedure.11 All patients underwent a major
vascular surgical procedure between 1990 and 2008, which
included open lower extremity revascularization, aneurys-
matic abdominal aortic surgery, or carotid surgery. From
1990 until 2001, standard preoperative screening included
a detailed cardiac history, physical examination, electrocar-
diogram, standard laboratory measurements, and addi-
tional stress testing if indicated. After 2002, standard pre-
operative echocardiography was added to the screening
program.
Body mass index. Before surgery, body weight (kg)
and length (m) were measured in all patients, and BMI was
calculated (kg/m2). The National Institutes of Health
obesity classification12 was used to divide the study popu-
lation into the following four BMI categories (kg/m2):
underweight (BMI 18.5), normal weight (BMI 18.5-
24.9), overweight (BMI 25-29.9), and obese (BMI 30).
Baseline characteristics. Medical records of every pa-
tient visit were reviewed by two authors (J. P. K. and
W. J. F.) to determine the presence of documented CAD
and cerebrovascular disease. CAD was defined as a docu-
mented history of ischemic heart disease (composite of
angina pectoris, myocardial infarction, percutaneous coro-
nary intervention, or coronary artery bypass grafting). The
presence of coronary ischemia was established by one of the
following techniques: exercise electrocardiogram, exercise
testing with echocardiography, or computed tomogra-
phy.13 Patients with stable or unstable angina pectoris were
classified as having documented CAD. Documented cere-
brovascular disease was defined as a history of cerebrovas-
cular accident or transient ischemic attack (confirmed by a
computed tomography scan). Lower extremity arterial dis-
ease was defined as current intermittent claudication with
ankle-brachial index0.9 or a history of intermittent clau-
dication with a previous intervention. Polyvascular disease
was defined as the presence of more than one affected
Fig 1. Flow diagram shows the source and final study popula-
tion.vascular beds. mMedication use and risk factors. The use of the
ollowing medication was recorded at discharge: aspirin,
tatins, -blockers, diuretics, angiotensin-converting en-
yme (ACE) inhibitors, calcium antagonists, and angioten-
in receptor blockers. According to the European Society of
ardiology guidelines, PAD patients have to be treated
ith aspirin (75-325mg), statins (low- to intermediate-risk
atients: target low-density lipoprotein-cholesterol [LDL-
] level 100 mg/dL, high-risk patients 70 mg/dL),
nd -blockers in patients with ischemic heart disease, and
hose with a left ventricular ejection fraction 40% should
eceive ACE inhibitors.14
Risk factors determined at baseline included age, gen-
er, smoking status, hypertension (blood pressure140/90
mHg in nondiabetics and130/80mmHg in diabetics or
equirement of antihypertensive medication), diabetes melli-
us15 (fasting blood glucose 7.0 mmol/L or requirement
or insulin or oral antidiabetic medication), hypercholesterol-
mia (LDL-C 135 mg/dL or the requirement of lipid-
owering medication, or both), chronic heart failure, and
hronic obstructive pulmonary disease (COPD), according to
he Global Initiative on Obstructive Lung Diseases classifica-
ion.16 Control of cardiovascular risk factor was defined in line
ith theEuropean Society ofCardiology guidelines,14 includ-
ng systolic blood pressure 140 mm Hg, diastolic blood
ressure90mmHg, LDL-C100mg/dL (2.5mmol/L),
lycemia 110 mg/dL (6.1 mmol/L), and smoking cessa-
ion 12 months. Good control was defined as three to five
ardiovascular risk factors at target values andpoor controlwas
efined when zero to two cardiovascular risk factors were at
argets.6
End points. The median follow-up of all patients was
years (interquartile range, 2-9 years). The primary study
nd point was the occurrence of all-cause mortality. Sur-
ival was assessed by querying the municipal civil registries.
ause of death was ascertained by examining death certifi-
ates or by reviewing medical records.
Statistical analyses. Dichotomous data are described
s numbers and percentages. Continuous variables are de-
cribed as means  standard deviation. Continuous data
ere compared using analysis of variance, and categoric
ata were compared using a 2 test. Cumulative survival of
he BMI groups was determined by the Kaplan-Meier
ethod and compared using the log-rank test. Cox regres-
ion models were used to investigate the association be-
ween BMI groups (patients with normal BMI as reference
roup) and death during long-term follow-up. Censoring
or the 311 patients with repeated surgery was performed at
he second surgical procedure.
All multivariate analyses were primarily adjusted for
emographics (age and gender), cardiovascular risk factors
smoking, hypertension, diabetes mellitus, dyslipidemia,
hronic heart failure, and COPD), site of surgery (lower
xtremity, abdominal aortic, or carotid), year of surgery,
epeated surgery during follow-up, history of malignancy,
nd medication use as recommended in PAD patients,
ncluding aspirin, statins, and -blockers, in case of prior
yocardial infarction, and ACE inhibitors in patients with
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Volume 53, Number 2 van Kuijk et al 401heart failure.4 To evaluate the effect of discharge use of
aspirin, statins, -blockers, and ACE inhibitors on long-
term outcome, multivariate Cox regression analyses were
performed with propensity score adjustment for each med-
ication. Separate propensity scores were developed with
logistic regression analyses for each type of medication.
Variables included in the propensity score were demo-
graphics (age and gender), cardiovascular risk factors
(smoking, hypertension, diabetes mellitus, dyslipidemia,
chronic heart failure, and COPD), site of surgery (lower
extremity, abdominal aortic or carotid), year of surgery,
repeated surgery during follow-up, and a history of malig-
nancy. To study the influence of polyvascular disease on the
BMI groups, we used interactions terms between BMI and
polyvascular disease. Statistical analyses were performed
using SPSS 15.0 software (SPSS Inc, Chicago, Ill). These
models were used to calculate hazard ratios (HRs), along
with their 95% confidence intervals (CIs). A value of P 
.05 (two-sided) was considered statistically significant.
RESULTS
Description of the study population. The final study
population consisted of 2933 patients referred for elective
major vascular surgery (Fig 1). Abdominal aortic surgery
was performed in 1170 (40%), lower extremity revascular-
ization in 1031 (35%), and carotid surgery in 732 patients
(25%). At baseline, the 2933 patients were categorized into
Table I. Baseline characteristics of the study population
Variables
Underweight N
(n  68)
Demographics
Age, mean  SD years 66  12
Male, No. (%) 38 (56)
History, No. (%)
Malignancies 33 (49)
CVA/TIA 11 (16)
Lower extremity PAD 24 (35)
Aortic aneurysmatic disease 3 (4)
Ischemic heart disease 22 (32)
Cardiovascular risk factors, No. (%)
Smoking
No 27 (40)
Current 32 (47)
History 9 (13)
Hypertension 21 (31)
Diabetes mellitus 8 (12)
Dyslipidemia 10 (15)
Chronic heart failure 3 (4)
COPD 8 (12)
Medication at discharge, No. (%)
Aspirin 17 (25)
Statin 15 (22)
-blocking agents 20 (29)
Diuretics 11 (16)
ACE inhibitors 9 (13)
Calcium antagonists 15 (22)
Angiotensin receptor blockers 2 (3)
ACE, Angiotensin-converting enzyme; COPD, chronic obstructive pulmonpreoperative BMI groups and included 68 underweight p2.3%), 1379 normal-weight (47.0%; reference group),
175 overweight (40.0%), and 311 obese patients (10.7%;
able I). A positive history of malignancies was less often
bserved in patients who were overweight (188 of 1175
16%]) or obese (44 of 311 [14%]). The distribution of the
urgical procedures is described in Fig 2. Patients with
ormal weight most often had lower extremity revascular-
zation compared with the other groups (P  .01). In the
otal study population, coronary artery disease was detected
n 1248 patients (43%) and cerebrovascular disease in 1037
ig 2. Distribution of the sites of the surgical procedures are
hown for the body mass index groups, including lower extremity
evascularization, abdominal aortic surgery, and carotid surgery.
l (reference) Overweight Obese
P 1379) (n  1175) (n  311)
7  12 67  10 64  11 .001
40 (75) 901 (77) 210 (68) .001
59 (26) 188 (16%) 44 (14) .001
69 (34) 447 (38) 110 (35) .001
89 (28) 257 (22) 96 (31) .001
34 (3) 25 (2) 5 (2) .50
57 (40) 535 (46) 134 (43) .02
.02
22 (38) 462 (39) 128 (41)
46 (40) 415 (35) 99 (32)
11 (23) 298 (25) 84 (27)
65 (48) 646 (50) 182 (59) .001
78 (13) 208 (18) 97 (31) .001
47 (25) 334 (28) 107 (24) .001
02 (7) 83 (7) 18 (6) .63
73 (20) 219 (19) 57 (18) .38
70 (49) 621 (53) 194 (62) .001
54 (33) 501 (43) 161 (52) .001
75 (42) 529 (45) 169 (54) .001
85 (21) 293 (25) 107 (34) .001
30 (24) 300 (26) 101 (35) .002
17 (23) 300 (26) 79 (25) .45
49 (4) 77 (7) 29 (9) .001
sease; CVA/TIA, cerebrovascular accident/transient ischemic attack.orma
(n
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February 2011402 van Kuijk et alShort-term and long-term outcome. Of the 2933
patients, 112 died during the first 30 postoperative days,
for a mortality rate of 4.0%. Mortality rates by BMI group
were underweight, 4% (3 of 68); normal-weight, 7% (97 of
1379); overweight, 3% (35 of 1175); and obese, 5% (16 of
311). The difference in the mortality rates between these
groups was not statistically significant (P  .125). During
long-term follow-up, there were 1389 deaths (47%; Table
II). Mortality was 69% in underweight patients (49 of 68)
compared with 52% in normal-weight patients (717 of
1379), which was significant (P  .001). In contrast,
overweight and obese patients had significantly lower mor-
tality rates of 43% (507 of 1175) and 38% (118 of 311, P
.001), respectively. A noncardiovascular cause of death
occurred in 434 of 1389 patients (31%), of which 258
(59%) were cancer-related. Patients in the underweight
group demonstrated a 44% rate (30 of 68) of cancer-related
death compared with 23% for the normal-weight (317 of
1379), 22% for the overweight (259 in 1175), and 18% for
the obesity group (56 of 311), which was statistically
significant (P  .01). Univariate Kaplan-Meier curves for
mortality, stratified according the BMI groups, demon-
strated that underweight patients had lower survival rates
than patients with a normal BMI (Fig 3). In contrast,
overweight or obese patients had higher survival rates than
patients with a normal BMI. A log-rank test was used to
compare cumulative survival between underweight vs nor-
mal (P  .002), overweight vs normal (P  .001) and
obesity vs normal (P  .01).
After multivariate regression analyses, patients within
the lowest BMI group had an increased risk for mortality
(HR, 2.10; 95% CI, 1.45-3.03) compared with patients
within the normal-weight BMI (Table III). In contrast,
overweight patients had a reduced risk for mortality (HR,
0.77; 95% CI, 0.69-0.86). Other independent predictors
Table II. Primary cause of death of the study population
Primary cause of death
Patients
No. (%)
Cardiac arrhythmia, unspecified 27 (2)
Heart failure 122 (9)
Stroke 66 (5)
Hypovolemic shock 48 (3)
Acute myocardial infarction 180 (13)
Cardiovascular disease, unspecified 335 (24)
Septicemia 36 (3)
Cancera 260 (19)
Complications of surgical and medical care
not elsewhere classifiedb 29 (2)
Chronic obstructive lung diseasec 85 (6)
Pneumonia and influenzad 22 (1)
Symptoms, signs, and abnormal clinical or lab
findings, not elsewhere classified 73 (5)
Ill-defined and unknown causes of mortality 106 (8)
Total 1389 (100)
Of these groups, 35,a 14,b 12,c and 10d were classified as a secondary cause
of death due to secondary cardiac complications.for mortality were age (HR, 1.05; 95% CI, 1.04-1.06), 0OPD (HR, 1.30; 95% CI, 1.14-1.48), diabetes mellitus
HR, 1.25; 95% CI, 1.08-1.45), and chronic heart failure
HR, 1.47; 95% CI, 1.21-1.79).
Polyvascular disease and outcome. Polyvascular dis-
ase was present in 28 of 68 underweight (41%), in 703
f 1379 normal-weight (51%), and in 817 of 1486
verweight and obese patients (55%; P  .02). When
nteraction terms were used to identify the direct influ-
nce of polyvascular disease on the relations between
MI and survival rates, no direct interaction was ob-
erved between the different BMI groups and polyvascu-
ar disease for long-term survival. In additional subgroup
nalyses, patients were subdivided into two groups with
ither BMI 25 kg/m2 or BMI 25 kg/m2. In both
roups, the presence of polyvascular disease was associ-
ted with reduced long-term survival rates. Kaplan-
eier long-term survival estimates are demonstrated in
ig 4. In both groups, the presence of multiply affected
ascular beds was associated with an increased mortality
isk during long-term follow-up. In multivariate analy-
es, patients with BMI 25 kg/m2 or BMI 25 kg/m2
nd concomitant polyvascular disease had an indepen-
ent increased mortality risk (HR, 1.22; 95% CI, 1.05-
.42 and HR, 1.33; 95% CI, 1.13-1.58) compared with
atients without polyvascular disease.
Medication use and risk factor control. Medication
se at discharge demonstrated an undertreatment of under-
eight patients compared with overweight or obese pa-
ients. The standard cardioprotective medical treatment for
AD patients included aspirin, statins, -blockers, and
CE inhibitors. Fig 5 provides an overview of the number
f drugs per BMI category and shows that 34 of 68 (50%)
f the underweight patients received no medical treatment
t discharge. A significant trend for more use of these four
ypes of drugs was observed in patients with higher BMI
ompared with patients with lower BMI (P  .001). Dur-
ng the follow-up period, aspirin (HR, 0.71; 95% CI,
ig 3. Cumulative survival is shown by Kaplan-Meier analysis of
he risk of all-cause mortality stratified according the four body
ass index groups..63-0.80) and statins (HR, 0.69; 95% CI, 0.59-0.80)
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Volume 53, Number 2 van Kuijk et al 403were significantly associated with lower mortality rates in
propensity-adjusted analyses.
The atherosclerotic risk factors of hypertension, diabe-
tes mellitus, and dyslipidemia were related to higher BMI
because the prevalence in patients with obesity was signifi-
cantly higher (P .001) compared with lower BMI. Mean
preoperative systolic and diastolic blood pressure for the
total were 148  48 and 82  25 mm Hg, and no
significant differences between the BMI groups were ob-
Table III. Long-term survival of all patients
Events No. (%)
All-cause mortality
Underweight 49/68 (72)
Normal 717/1379 (51.9)
Overweight 507/1175 (43.1)
Obesity 118/311 (37.9)
CI, Confidence interval; HR, hazard ratio.
aAdjustment for age, gender, polyvascular disease, smoking, hypertensio
pulmonary disease, site of surgery, year of surgery, aspirin, statins, and -bl
Fig 4. Kaplan-Meier estimates show cumulative surviv
polyvascular disease in patients with a (left) body mass i
Fig 5. Number of drugs used at the time of discharge for each
body mass index group, including aspirin, statin, -blockers, and
angiotensin-converting enzyme inhibitors.served (P  .55). 5Preoperative mean high-density lipoprotein-cholesterol
HDL-C) was highest in the underweight group (53.0 
9 mg/dL [1.37  0.50 mmol/L]) and lowest in the
besity groups (43  13 mg/dL [1.10  0.34 mmol/L];
 .001).Mean LDL-C of the total population was 123
8 mg/dL (3.19  1.24 mmol/L), and no significant
ifferences in mean preoperative LDL-C were observed
mong the BMI groups.
Several important differences between gender, smok-
ng habits, and the BMI groups were observed. Of the 30
nderweight women, 15 (50%) were current smokers
ompared with 32 of the 101 obese women (32%). In
ddition, only 1 underweight woman (3%) stopped
moking compared with 136 of 714 women (19%) in the
ther BMI groups. In the men, the number of previous
mokers showed a clear association with the increase in
MI: 8 of 38 (21%) of the underweight men and 65 of
10 (31%) of the obese men were previous smokers. The
umber of current smokers decreased from 17 of 38
45%) in underweight men to 67 of 210 (32%) in obese
en. Finally, in all patients, current smoking was not an
ndependent predictor of increased mortality risk; how-
ver, those patients who stopped smoking had a signifi-
antly lower mortality risk (HR, 0.84; 95% CI, 0.72-
.98) compared with those who continued smoking.
here were no differences between the BMI groups
egarding the number of controlled cardiovascular risk
actors. Good control (3 to 5 risk factors controlled) was
chieved in 53% (36 of 68) of the underweight group
ompared with 54% (745 of 1379) of the normal-weight,
variate HR (95% CI) Multivariatea HR (95% CI)
1.60 (1.19-2.15) 2.10 (1.45-3.03)
Reference Reference
0.76 (0.68-0.86) 0.77 (0.69-0.86)
0.78 (0.64-0.95) 0.93 (0.76-1.13)
abetes mellitus, hypercholesterolemia, heart failure, chronic obstructive
.
atified according to the presence of monovascular or
25 kg/m2 or (right) 25 kg/m2.Unial str3% (623 of 1175) of the overweight, and 55% (171 of
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February 2011404 van Kuijk et al311) of the obesity group (P  .88). In separate analyses
for individual risk factors, significant differences were
only detected for target LDL-C 100 mg/dL (2.5
mmol/L). Underweight patients had the lowest effect
rate of statin therapy, as only 6 of 68 (9%) received the
target compared with 179 of 1379 (13%) normal-
weight, 188 of 1175 (16%) overweight, and 62 of 311
(20%) obese patients (P  .005).
DISCUSSION
The current study demonstrated that overweight pa-
tients had a reduced long-term mortality risk. We observed
a low prevalence of polyvascular disease in patients with low
BMI compared with a significantly higher prevalence in
patients with BMI 25 kg/m2. The increased prevalence
of polyvascular disease in overweight and obese patients
was independently associated with an increased mortality
risk; however, no direct interaction between BMI and
polyvascular disease was observed. Medical treatment at
time of discharge in overweight and obese patients was
highest, because only 18% of these patients received no
treatment. Remarkably, risk factor control was achieved
equally in all treated BMI groups.
In the pathogenesis and complications of obesity, the
adipocyte has a substantial role acting as an endocrine
organ.17 Food intake and energy metabolism is controlled
by the hormone leptin, which is derived from adipocytes.
Increased leptin levels have been related to the develop-
ment of cardiovascular disease.18 On the one hand, obesity
stimulates the development of leptin resistance, which in
turn influences insulin resistance and eventually results in
type II diabetes mellitus. On the other hand, obesity pro-
motes hyperleptinemia, which stimulates increasing blood
pressure through adverse effects on the vascular wall.18
Several studies, however, have not been able to demon-
strate a clear role for leptin.
Other more recent studies have demonstrated the in-
volvement of other adipokines and the immune system
through low-grade inflammation of adipose tissue, re-
flected by C-reactive protein elevations.19,20 These patho-
physiologic mechanisms are important in the atheroscle-
rotic process, a systematic inflammatory disease with
clinical presentations in multiple vascular beds. Obesity has
been identified as an important risk factor for developing
CAD; however, once this has been established, the corre-
lation between obesity and mortality is paradoxic. There-
fore, other factors, such as the presence of polyvascular
disease ormedical undertreatment, could be involved in the
obesity paradox on long-term outcome.
The obesity paradox has extensively been described in
patient cohorts with established CAD. A meta-analysis by
Romero-Corral and colleagues summarized these studies
and demonstrated that patients with overweight and mild
obesity had lower mortality rates than normal-weight pa-
tients.10 In contrast, patients whowere underweight had an
increased all-cause and cardiovascular mortality risk com-
pared with normal-weight patients.10 The obesity paradox
was also recently demonstrated in a cohort of almost 5000 ratients undergoing percutaneous coronary intervention.8
ullen et al21 demonstrated that overweight and moder-
tely obese patients in the general surgery population have
aradoxically lower crude and adjusted risks of mortality
ompared with normal-weight patients. Galal et al22 have
hown an excess mortality rate among underweight pa-
ients with PAD, which was largely explained by the over-
epresentation of individuals with moderate-to-severe
OPD.
Our study results are in line with these studies regard-
ng the paradoxically increased mortality rates in under-
eight patients during long-term follow-up. Short-term
ostoperative outcome was not associated with an in-
reased mortality risk for one of the BMI groups compared
ith normal weight. The survival curves suggest an in-
reased mortality risk for the underweight patients; how-
ver, this is very likely a result of the small number of
atients in this group.
Gulsvik et al23 demonstrated a U-shaped risk curve for
otal mortality in the elderly, which was confirmed by our
esults in high-risk vascular surgery patients. Furthermore,
verweight was associated with a survival benefit compared
ith normal weight; however, obesity showed no relation
ith an increased or decreased mortality risk. In the present
tudy, we used the National Institutes of Health obesity
lassification12 to study the associations with the obesity
aradox. It could be argued that cohort should be defined
nto four equal BMI quartiles because this could have more
tatistical significance. However, the main purpose of the
resent study was to provide the clinician with a practical
nd easy applicable definition; therefore, we used the pre-
efined BMI groups.
More important, although several possible explana-
ions for the obesity paradox have been suggested, the
nfluence of polyvascular disease has not been investigated.
e demonstrated that overweight and obese patients had a
ignificant increased incidence of polyvascular disease com-
ared with a low incidence in underweight patients. Re-
arkably, patients with BMI 25 kg/m2 or BMI 25
g/m2 and concomitant polyvascular disease had an in-
reased mortality risk compared with those without poly-
ascular disease. Because no direct interaction between
MI, polyvascular disease and long-term mortality was
bserved, it cannot be concluded that polyvascular disease
s an explanation for the obesity paradox.
In the present study, patients with low BMI received
ess frequent medical treatment at discharge compared with
verweight or obese patients. Results from the Get With
he Guidelines Database in CAD patients showed that
igher BMI was associated with increased use of standard
edical therapies such as aspirin, -blockers, ACE inhibi-
ors, and lipid-lowering therapies.24 This relation between
MI and treatment rates may represent the response of
hysicians to a more visible risk factor compared with the
ess visible traditional risk factors such as hypertension and
iabetes. However, because obese patients had an increased
ncidence of polyvascular disease, this could also be the
eason for intensified treatment.
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Volume 53, Number 2 van Kuijk et al 405In the present study, the low and normal BMI groups
were consistently associated with a lower prevalence of
established cardiovascular risk factors, with the exception of
current smoking. Therefore, these BMI groups were less
likely to receive effective secondary prevention therapies
such as lifestyle interventions and medical treatment. In
contrast, overweight and obese patients received more ag-
gressive medical treatment. Because overweight and obese
patients are younger at first presentation, a more aggressive
treatment strategy may be performed.
The importance of socioeconomic status and dietary
habits also needs to be acknowledged. These are known risk
factors for developing overweight and have been associated
with adverse long-term outcomes.25,26 Although over-
weight seems to have a protective perioperative effect, and
overweight patients are more likely to receive earlier and
extended medical attention, they remain at increased risk
for developing metabolic and cardiac complications due to
their increased body weight.
Even though low BMI patients received less intensive
medical treatment at the time of hospitalization, risk factor
control intensity in those patients who did receive treat-
ment was comparable with the other BMI groups. Of note,
statin therapy was an independent predictor for increased
survival rates; however, LDL-C lowering could be less
efficient in patients with low body weight. Our results
emphasize the importance of risk factor stratification and
modification in vascular surgery patients with a low BMI,
while adequate medical treatment at discharge was associ-
ated with improved survival rates in all groups of patients.
Potential limitations of the current study merit consid-
eration. First, this study has the disadvantage of a retrospec-
tive design and included a patient population of vascular
surgery referrals that might not be fully representative for
the general population.
Second, although suggested by the survival curves,
short-term postoperative mortality (30 days) was not sig-
nificantly different among the BMI groups. This is very
likely a result of the small number of patients in the under-
weight group, and these results need to be interpreted with
some caution.
Third, the results of this study showing significant
associations between medical treatment at discharge and
increased survival rates need to be interpreted with some
caution because no evaluation of treatment adherence dur-
ing follow-up was available.
Fourth, because AAA development is not causally re-
lated to the presence of atherosclerotic disease, although
there are many common risk factors, appropriate medical
therapy could be underestimated in these patients.
Finally, data on socioeconomic status and dietary habits
were not available, and therefore, we cannot rule out the
possibility of confounding by these factors. In addition,
although we adjusted the multivariate analyses for possible
confounders (smoking, cancer, medical treatment) of the
primary end point, we cannot rule out the possibility of
residual confounding.
1ONCLUSIONS
In this population of vascular surgery patients, more
han half were categorized as overweight or obese. The
revalence of polyvascular disease was significantly higher
n patients who were overweight or obese. The high prev-
lence of polyvascular disease in overweight and obese
atients was independently associated with increased mor-
ality compared with patients with monovascular disease;
owever, no direct interaction between polyvascular dis-
ase and BMI was observed. A significant trend for less
edical treatment at discharge in relation to decreasing
MI was observed. Underweight patients were at an in-
reased long-term mortality risk, whereas overweight pa-
ients had a reduced mortality risk compared with normal-
eight patients.
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The obesity paradox, where the survival of underweight pa-
tients is worse than in patients with a body mass index within
normal reference ranges, has been described in several groups of
patients, particularly those with heart failure or renal failure as well
as in patients with peripheral arterial disease. These studies, all
retrospective and relatively small with just a few thousand patients,
sometimes show an inverse relationship between survival and body
mass index and sometimes a U-shaped curve demonstrating the
highest mortality for very underweight and obese patients.
No prospective studies have been designed to take into con-
sideration the many confounders present in these retrospective
observational studies. These confounders include selection for
treatment, treatments given, the cachexia of cancer, heart failure,
and severe chronic obstructive pulmonary disease, malnourish-
ment, smoking, and diabetes.
Here van Kuijk et al1 describe a retrospective series of patients
undergoing vascular surgical procedures where survival was better
in the overweight and obese patients was than in patients of normal
weight, and survival was worst in the cachectic or underweight
patients. Death is a “hard” end point and reliable for retrospective
studies, but the cause of death is not reliable. Although their Fig 1
suggests that the causes of death could be divided into cardiovas-
cular, noncardiovascular, or unknown, it is difficult enough to
reliably categorize cause of death in prospective studies with an end
point committee and almost impossible to categorize deaths inNutritional status is likely to be an important predictor of
ealing after surgery. It is unsurprising that underweight patients
ave a poor outcome, and in the series reported by van Kuijk et al,1
he prevalence of cancer was higher than in the other groups.
erhaps the high-risk overweight patients were refused surgery,
nderweight patients were refused secondary interventions, or
erhaps overweight patients had more endovascular procedures
nd the underweight patients more open procedures? Also, surpris-
ngly, the overweight patients appeared to have the best medical
anagement of cardiovascular risk factors. Confounders such as
hese serve to highlight the limitations of retrospective studies.
hey are useful for audit and hypothesis generation, but the
ypotheses generated need to be evaluated in prospective studies.
Prospective evaluation of the obesity paradox in vascular sur-
ical patients is likely to require tens of thousands of patients. Is it
orth it? Possibly, if better understanding of the endocrine and
mmune functions of adipose tissue in vascular patients leads to
etter treatment for all patients.2,3
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